A heated debate has emerged in the healthcare industry, with a private healthcare third-party administrator, MiCare, finding itself at the center of controversy. The issue? A policy that allows only generic medication to be dispensed, leaving many health professionals and organizations questioning its implications.
On November 14, 2025, MiCare defended its stance, stating that banks retain full control over the scope and limits of medical treatment for their employees. This policy directive has sparked a lively discussion, with health-related organizations voicing their objections.
In a letter addressed to its panel clinics, MiCare clarified its role, emphasizing its responsibility to evaluate, process, and administer medical claims as directed by the banks, within the boundaries of applicable laws and regulations.
However, here's where it gets controversial: MiCare's letter also states that employees must bear the cost of prescribed medications or treatments that fall outside the parameters set by the banks. In other words, if an employee opts for patented medicine or treatments not covered by their medical entitlement, they will be responsible for the additional expenses.
MiCare further clarified that while it respects the clinical autonomy of doctors in determining appropriate medical treatment, it also has contractual obligations with the banks. This means that private clinics must adhere to the eligibility requirements based on the bank's policy, or risk losing their panel status.
A private general practitioner, speaking anonymously, expressed concern over this policy, stating that it limits doctors' discretion in medication dispensation and treatment choices.
The Malaysian Medical Association (MMA) has also criticized this blanket generic-only mandate, arguing that it undermines doctors' professional ethics, patient rights, and the true care of non-communicable diseases. MMA, as the country's largest doctors' association, highlights that the Private Healthcare Facilities and Services Act 1998 and the health ministry's guidelines explicitly prohibit managed care organizations and TPAs from interfering in clinical decision-making.
So, the question remains: Is this policy a necessary cost-cutting measure, or does it infringe on the rights and autonomy of healthcare professionals and patients? What are your thoughts on this controversial issue? Feel free to share your opinions and engage in a constructive discussion in the comments below!
